Bone Therapeutics is committed to implementing the highest processes and standards of corporate governance, while ensuring that its business model is relevant, efficient and cost effective to the Company and its investors.
The Board of Directors is made up of the Chairman, eight non-executive Directors (five of which are independent) and two executive Directors.
Michel Helbig de Balzac has a long-standing experience in venture capital as the Founder and Managing Partner of BAMS Angels Fund I SCA (founded in 2005) and Nausicaa Ventures SCA (2009), both investing in early stage and early growth new technology companies and located in Louvain-la-Neuve (Belgium). He has particular knowledge in the fields of biotech, medical devices and energy, and represents the funds at the board of several investee companies such as Spacebel, Ovizio, and Bio-Sourcing. He serves as the Chairman of the Board of Directors of Bone Therapeutics since June 2013. Previously, he was an acknowledged angel investor and entrepreneur with several high-growth companies. Complementary to venture capital, he has been very active in the development and financing of large-scale renewable energy development projects such as the North Sea offshore wind farm Northwester 2 consortium, comprised of Colruyt, TTR Energy (TPF Group), Incontrol, and his own company Wagram Invest, which was granted a 224 MW area concession in 2013. From 2002 to 2013 he was influential in helping to launch a range of wind farm projects in the Walloon Region. From 2009 to 2014, he was the Chairman of Edora, the Belgian Federation for Renewable Energy, of which he is currently Vice-Chairman, and more recently a board member of the Belgian Offshore Platform association. Michel started his professional career in 1985 with McKinsey, where he was active in the steel and paper industries and the insurance and hospital sectors before taking on the responsibility of Administrative Director and General Secretary of their Brussels Office. He then joined Dewaay Bank in 1994 where he led the development of various private banking and corporate finance projects. Michel has a broad academic background from UCL (Belgium) in philosophy, political sciences (with a focus on international relations), economic sciences, and European studies, and a MSc degree in Urban and Regional Planning (access to final work).
Pr. Roland Baron is professor at the Harvard Medical School, Endocrine Unit, Massachusetts General Hospital, and Chair of Oral Medicine at the Harvard School of Dental Medicine from January 2008. He received his DDS and PhD degrees from the University of Paris, France. From 1977 to 2007, Pr. Roland Baron was a professor in the departments of Orthopaedics and Cell Biology at Yale University School of Medicine. From 1994 to 2002, he also held the position of Vice President and Head of the Bone Diseases Group at Hoechst Marion Roussel and then Aventis. In 2002 he founded ProSkelia, a small pharmaceutical company devoted to the discovery and development of new drugs for bone and hormonal dependent diseases. He has held the positions of President and Chief Scientific Officer of ProSkelia and then ProStrakan, until April 2006. He is the founder and current Editor-in-Chief of BONE, the Official Journal of the International Bone and Mineral Society. Pr. Baron has published over 300 scientific papers in the field of bone biology and bone diseases.
Chris Buyse holds a Master’s degree in Applied Economics from the University of Antwerp and an MBA from the Vlerinck School of Management in Ghent. From August 2006 to 2014, Chris was CFO and Director of ThromboGenics NV, a biotechnology company listed on NYSE Euronext Brussels. Before joining ThromboGenics , he was CFO of CropDesign , where he coordinated the acquisition by BASF in July 2006. Prior to joining CropDesign, he served as finance manager WorldCom/MCI Belux, and CFO and CEO ad interim of Keyware Technologies. Before, Chris kept positions in finance at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever. He currently holds a Director position in several private companies.
Paul Magrez is a Medical doctor and computer scientist with more than 20 years of experience in diagnostics (personalized medicine), clinical biology, biotechnology (vaccines), and pharmaceutical industries. His experience mainly resides in the development of business plans, the search for private and public funding and the business & commercial development. After working at UCB as Data Management R&D Manager from 1988 to 1992, he moved on to GSK, to take position as Information Resource Director (from 1992 to 1997) and Executive Director Business Operations (from 1997 to 2001). In 2001, he became the COO and CEO ad interim of Innogenetics until 2007, when he took position as CEO of Biomedical Diagnostics in Paris. From 2009 to 2011, he was CEO and Chairman at BARC. In 2011, Paul founded his own consulting firm in support of SMEs and start-ups, Paul Magrez BVBA.
Marc Nolet de Brauwere obtained his Master’s degree as a Mining Civil Engineer from the Catholic University of Louvain (UCL) in 1982, then specialized as a Civil Engineer in Industrial Management at the Katholiek Universiteit Leuven (KUL) in 1983. He started his career in 1984, as Manager of the Engineering department at Petrofina (Kentucky Prince Coal Corporation). In 1978, he also took charge of the development of a downstream activity (gold mining) at Chemetech Corporation. He served for these two companies until 1989, then moved on to McKinsey & Company, as an Associate. In 1992, Marc created Dat International SA with an ex-colleague of McKinsey, and set up a distribution network specialized in supply parts from the EEC to local companies in East Africa. Finally, in 1997, he became CEO of Physiol SA. Besides, he was nominated Director at ETEX group in 2003, where he served as chairman of the Audit committee from 2006 to 2013. He became Chairman of the Nominations and Remunerations Committee in 2013. In addition, he became Director of Mecatech (2011), Biotech Coaching (2011), MyMicroInvest (2013) and EndoTools Therapeutics (2013). Since 2011 he also is a member of Ashoka Support Network since 2011.
Thierry François (permanent representative of Magenta Tree BVBA) holds a Master’s degree of Science in Engineering and Management, as well as Guberna certificates. He is also a CFA charterholder and a Certified Financial Analyst (EFFAS). With more than 20 years of experience in corporate finance, sell side equity research and private equity, he is a true expert in financial analysis, with a strong background in competitive strategy, financial and legal structuring, and business valuation. He started his career in 1993 as a university trainee at the BNP Paribas Fortis Bank (Generale de Banque at the time), and worked his way up to corporate research officer (1994-1997). He then moved on to Vermeulen-Raemdonck (part of ING Bank), where he served as a senior financial analyst. In 2000, he returned to Fortis Bank, to take the position as director equity research (2000-2004) and later as head of investment analyst (2004-2011). Since, he operated as an independent investment professional, for companies such as Korys, Sofindev II and III, and Re-Vive Brownfield Fund II. Finally, he is the founder and owner of Magenta Tree.
Jean-Jacques Verdickt holds a Master’s degree in mechanical engineering from the Leuven Catholic University (UCL). He started his career in 1971 at the BNP Paribas Fortis Bank (Generale de Banque at the time), and worked his way up from management roles to director and senior advisor to the chairman of Fortis Bank. In 2003, he became the chief executive officer of Magotteaux (until December 2006). He now serves as non-executive director of various companies, such as Techspace Aero, FREE, Euroclear (Plc and Bank), IBA SA, Logiver, Union Wallonne des Entreprises, and other non-profit organizations.
Dr. Jean-Paul Prieels, Ph.D, served as a Senior Vice President of Research & Development at GlaxoSmithKline Biologicals until 2011. Dr. Prieels joined GlaxoSmithKline Biologicals in 1987 as an Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium. His career spans from basic research to process and product development. He was instrumental in developing several commercially available vaccines, such as rotavirus, human papilloma virus (HPV), pneumococcal conjugates and others. He served as Head of Research at GSK Vaccines. Dr. Prieels has been a Director of Okairos AG since 2011. He serves Chairman of Immune Health. He has been a Director of TheraDiag SA since 2012. Since 2007, he has been a Member of the Scientific Advisory Board of the Singapore Bioprocessing Technology Institute. He serves as a Director of Vaximm AG. He serves as a Director and Member of Scientific Advisory Board of ABIVAX S.A. He serves as a Member of Scientific Advisory Board at MolMed S.p.A. He was a Board Member of Pevion Biotech AG since 2011 and Henogen from 2000 to 2008. Dr. Prieels graduated from the Free University of Brussels, Belgium, and holds a PhD in Biochemistry from Universite Libre de Bruxelles in Belgium.
Mr. Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry. Prior to joining Bone Therapeutics, Mr. Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. Before his position at Lundbeck, Mr. Lienard worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Mr. Lienard started his career in 1999 as consultant at McKinsey & Company. Mr. Lienard graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004. Mr. Lienard joined Bone Therapeutics in 2015 as Chief Business Officer in charge of activities regarding business development and strategic planning and was appointed CEO in October 2016.
Mr. Goemaere is an experienced senior financial executive with over 25 years international business experience, the majority of which he spent within the biotechnology field. After graduating in applied economics from KU Leuven (Belgium) in 1987, he began his career at BP where he held various finance roles with increasing responsibility until leaving the Company in 1995, to join the Flanders Institute for Biotechnology (VIB) as CFO. Mr. Goemaere played a key role in the Institute's development from start-up to one of the world's leading research bodies in life sciences. In 2008, he moved to Devgen, a Belgium-based multinational agro-biotech company listed on NYSE Euronext Brussels, where he held the position of CFO for five years. Mr. Goemaere was instrumental in ensuring endorsement of Devgen in the financial markets and in the take-over of Devgen by Syngenta for €403 million. Furthermore, he played an important role into the company's business expansion in Asia.